enzh-TWfrdeitjaptrues

Date: 12/26/2004

Dr. Steven Treon presents a historical perspective on the research and treatment of Waldenstrom's macroglobulinemia. Using the Tour de France as a metaphor, he begins with the first description of the disease by Dr. Jan Waldenstrom in 1944, and recognizes the major contributions and milestones along the way. Paris 2004 is our current stop along the way to the "finish line".

A Short Hostory of WM (Part 2).
Running Time: 5:05
File Size: 2.99MB

Latest Bing Center News

2021 IWMF Global Educational Webinar with Dr. Stephen Ansell & Dr. Jorge Castillo

2021 IWMF Global Educational Webinar with Dr. Stephen Ansell & Dr. Jorge Castillo

Our IWMF experts will share an update on the status of existing COVID-19 vaccines and others in development. This interactive LIVE question and answer session will explain side effects and recommendations for WM patients.

Read more..

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely — while reaching more people, quickly and cheaply.

Read more..

Current and Future Treatments for Waldenstrom Macroglobulinemia

Current and Future Treatments for Waldenstrom Macroglobulinemia

What are the treatments for Waldenstrom macroglobulinemia and what's in the pipeline? Can Waldenstrom patients plan for a higher quality of life? Dr. Jorge Castillo, Clinical Director, Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, presents an overview of his presentation at the 2020 IWMF with Patient Power co-founder Andrew Schorr.

Read more..

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Workshop Date and Time: Wednesday, April 21, 2021, 12:30 – 1:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast.

Read more..

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou and Meletios A. Dimopoulos present a summary of trial findings and details regarding various BTK inhibitors, including ibrutinib, zanubrutinib, acalabrutinib, tirabrutinib, LOXO-305, etc.

Read more..

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). The Prescription Drug User Fee Act (PDUFA) target action date is October 18, 2021.

Read more..

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

December 21, 2020: Dr. Jorge Castillo walks us through immunology basics, teaches us the limitations of the SPEP, plus some additional tests that complement it (think Immunofixation), shares his clinical gestalt about when to suspect MGUS, Myeloma, Waldenstrom’s, and Amyloidosis–and finally, how to talk to patients about them.

Read more..

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

Dear IMS Member: We hope you are well during these difficult times. As a response to the current pandemic, the International Myeloma Society has developed the following Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance.

Read more..

Cancer and the COVID-19 Vaccine

Cancer and the COVID-19 Vaccine

On January 27, Dana Farber held a webinar to review the information regarding COVID-19 vaccinations for patients. Catherine Flynn (from the Bing Center Clinic) shares the following highlights from the webinar.  Note, the entire webinar was recorded and posted to Facebook, using the following link:

Read more..

COVID-19 Facts and Resources

COVID-19 Facts and Resources

Based on the latest guidance we have received from the state of Massachusetts, we expect Dana-Farber's supply of COVID-19 vaccine for patients to be very limited in February and perhaps longer. We are working hard to place special focus on getting vaccines to our most at-risk patients, in compliance with the state's rollout guidelines, as we receive allotments of the vaccine.

Read more..